Fig. 1

Low DUSP4 expression in OC tissues is linked to poor prognosis. (A) Representative images of DUSP4 expression levels in human tumor tissue samples detected by immunohistochemical assay. The scale bar is 50 μm. (B) Statistical analysis of DUSP4 expression levels in benign cyst (n = 62), primary tumor (n = 116), and metastatic tumor samples (n = 71). P-value is determined by two-sided t test; the data is shown as mean ± SD; ns means no significant difference, and ***p indicates statistical difference. (C) Statistical analysis of the proportion of high and low DUSP4 expression levels in benign cyst (n = 62), and primary tumor samples (n = 116). (D) Expression levels of DUSP4 in different pathological types of ovarian cancer. Statistical analysis was performed using the Kruskal-Wallis test. *p indicates statistical difference. (E) Expression levels of DUSP4 in OC across different stages. Statistical analysis was performed using the Kruskal-Wallis test based on our dataset. ***p indicates statistical difference. (F) DUSP4 mRNA expression across different stages of OC using data from TCGA OV database. (G) Overall survival analysis of OC patients with high and low DUSP4 expression levels in tumor tissues using Kaplan-Meier curves. The level of significance and p-value is determined by log-rank test. (H-I) Survival analysis of OC patients with high and low DUSP4 expression levels in tumor tissues using data from TCGA and GEO database, including overall survival (H) and progression free survival rate (I) shown by Kaplan-Meier curves